Novo Nordisk expands US diabetes field force

Published: 4-Dec-2006

Novo Nordisk plans to expand its US diabetes care field force from 1,200 to approximately 1,900 people.


Novo Nordisk plans to expand its US diabetes care field force from 1,200 to approximately 1,900 people.

The expansion, which will take place during the first half of 2007, is designed to further strengthen the company's position in the US insulin market and to increase the company's 'share of voice' in the competitive market for diabetes products.

The US insulin market is a key growth market for Novo Nordisk and one for which it claims to hold more than a 40% share.

The expansion will support its complete insulin portfolio of Levemir, a long-acting insulin, NovoLog Mix 70/30, a premixed formulation of rapid-acting and intermediate-acting insulin, and NovoLog, a rapid-acting insulin.

  • Companies:
  • Novo Nordisk Pharmatech
See more

You may also like

Regulatory

Novo Nordisk’s oral semaglutide scores EU approval for cardiovascular benefits

Read more
Rybelsus is now the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke

Trending Articles

  1. Continuous innovation: redefining the future of pharmaceutical manufacturing In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
  2. Abselion launches AAVX and AAV9 Total Capsid Quantification Kits Ready-to-use solution for Amperia benchtop platform supports rapid, reliable quantification across a range of serotypes
  3. diaago and Peak Analysis & Automation partner to bring practical automation solutions to research laboratories Using diaago's customer-first approach with PAA’s decades of expertise in laboratory robotics, the collaboration promises to deliver solutions to streamline workflows, boost throughput and reduce bottlenecks
  4. Suncombe and Kindeva collaborate to deliver low-carbon inhalers to the NHS The partnership will develop next-generation pressurised metered-dose inhalers with low Global Warming Potential propellants, helping the NHS move closer to its Net Zero target
  5. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Regulatory

Novo Nordisk’s oral semaglutide scores EU approval for cardiovascular benefits

Rybelsus is now the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
Research & Development

Wegovy cuts risk of heart attack, stroke or death by 57% compared with tirzepatide

Study adds to growing evidence suggesting that the heart-protective benefits seen with Wegovy are specific to the semaglutide molecule and therefore cannot be extended to other GLP-1 or GIP/GLP-1-based treatments
Drug Delivery

BioMed X and Novo Nordisk launch new collaboration in oral peptide drug delivery

The initiative aims to identify and support new ideas for innovative oral formulations for peptide drugs such as GLP-1 receptor agonists via BioMed X’s global talent sourcing and incubation model

Wegovy approved by FDA to treatment adults with non-cirrhotic MASH with moderate to advanced liver fibrosis

The FDA has granted approval for Wegovy (semaglutide) injection 2.4 mg as the first GLP-1 receptor agonist to treat adults with moderate to advanced liver scarring because of MASH, marking a significant advancement in the management of this serious condition
Research & Development

Novo Nordisk's Wegovy effective in obese patients, Phase IIIb data suggests

A 7.2mg dose of semaglutide triggered an average weight loss of 21% in obese patients during a 72 week period
Finance

Weight loss drugs fuelling rapid big pharma growth, report reveals

Weight loss and diabetes medications are championing growth in key big pharma players, such as Novo Nordisk and Eli Lilly
Finance

Novo Holdings completes acquisition of Catalent

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark
Subscribe now